Pricing Log in Create free account

Cardiff Oncology, Inc. (CRDF) vs Heron Therapeutics, Inc. (HRTX)

Cardiff Oncology, Inc. and Heron Therapeutics, Inc. are both Biotechnology companies. Cardiff Oncology, Inc. and Heron Therapeutics, Inc. are of similar size ($75.5M and $71.5M). Heron Therapeutics, Inc. grew revenue faster over the last twelve months: 0.99% against −6.79%. Heron Therapeutics, Inc. has the higher net margin (−22.5% vs −7,889.0%) and the lower return on invested capital (−6.35% vs 0.00%). Across the 18 metrics below, Heron Therapeutics, Inc. leads on 12 and Cardiff Oncology, Inc. on 6.

Valuation

Metric CRDF HRTX Biotechnology median
P/E n/m n/m 8.50
P/S 122.52 0.45 9.71
P/B 2.35 11.70 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m n/m 0.64
EV/Sales 57.34 1.11 9.21
Earnings yield (65.93%) (52.78%) (33.15%)
Free cash flow yield (65.78%) (17.64%) (25.50%)

Profitability

Metric CRDF HRTX Biotechnology median
Gross margin 100.00% 70.07% 65.16%
Operating margin (8,320.08%) (7.19%) 0.00%
Net margin (7,888.98%) (22.52%) 0.00%
Free cash flow margin (8,059.45%) (8.00%) 0.00%
Return on equity (94.14%) 318.21% (56.36%)
Return on assets (70.89%) (14.06%) (48.04%)
Return on invested capital 0.00% (6.35%) 0.00%

Growth

Metric CRDF HRTX Biotechnology median
Revenue growth (TTM) (6.79%) 0.99% 6.02%
EPS growth (last fiscal year) 27.37% (33.33%) 30.26%
Revenue growth, 5-year CAGR 10.13% 11.81% 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric CRDF HRTX Biotechnology median
Debt to equity 0.00 20.65 0.00
Current ratio 3.30 2.49 4.72
Net debt to EBITDA 1.18 (643.88) 0.96

Dividend

Metric CRDF HRTX Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric CRDF HRTX Biotechnology median
Market cap 75.54m 71.48m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack